Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 14, Issue 2, 1998, Pages 159-168

  Siegner, S W ^a,b   Giovanoni, R L ^a   Erickson, K A ^a   Netland, P A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DRUG METABOLITE; NORVERAPAMIL; VERAPAMIL;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; GLAUCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; RABBIT; TOPICAL DRUG ADMINISTRATION; VITREOUS BODY;

EID: 0031977074     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1998.14.159     Document Type: Article

References (39)

1. Braunwald, E. Mechanisms of action of calcium-channel-blocking agents. N. Eitgl. J. Med., 307:1618-1627, 1982.
2. Gelmers, HJ. and Kennend, M. Effect of nimodipine on acute ischémie stroke: pooled results from five randomized trials. Stroke,21 (Suppl. IV):IV81-IV84, 1990.
3. Iversen, L.L. Pharmacological approaches to the treatment of ischaemic neuronal damage. Eye, 5:193-197, 1991.
4. Murphy, T.H, Malouf, A.T., Sastre, A., Schnaar, R.L, and Coyle, J.T. Calcium-dependent glutamate cytotoxicity in a neuronal cell line. Brain Res., 444:325-332, 1988.
5. Bussey, H.I. and Talbert, R. Promising uses of calcium-channel blocking agents. Pharmacotherapy, 4:137-143, 1984.
6. Abelson, M., Gilbert, C., and Smith, L. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am. J. Ophthalmol., 105:155-159, 1988.
7. Netland, P.A. Calcium channel blockers in glaucoma therapy. Ophthalmol. Clin. North Am., 10:357-364, 1997.
8. Netland, P.A., Grosskreutz, C.L., Feke, G.T., and Hart, L.J. Color Doppler ultrasound analysis of ocular circulation after topical calcium channels blocker. Am. J. Ophthalmol., 119:694-700,1995.
9. Netland, P.A., Feke, G.T., Konno, S., Goger, D.G., and Fujio, N. Optic nerve head circulation after topical calcium channel blocker. J. Glaucoma, 5:200-206, 1996.
10. Sawada, A., Kitazawa, Y., Yamamaoto, T., Okabe, I., and Ichien, K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology, 103:283-288, 1996.
11. Gasser, P. and Flammer, J. Influence of vasospasm on visual function. Doc. Ophthalmol., 66:3-18, 1987.
12. Böse, S., Piltz, J.R., and Breton, M.E. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with .normal-tension glaucoma and in control subjects. Ophthalmology, 102:1236-1241, 1995.
13. Netland, P.A., Chaturvedi, N., and Dreyer, E.B. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol., 115:608-613, 1993.
14. Weiner, B., Ajmera, P., and Arena, D. Verapamil hydrochloride. In Physicians' Desk Reference Generics. Medical Economics Company Data Staff, Medical Economics Company, Inc., Montvale, N.J., 1996, pp. 3076-3083.
15. Murad, F. Drugs used for the treatment of angina: organic nitrates, calcium-channel blockers, and -adrenergic antagonists. Jn The Pharmacological Basis of Therapeutics. Oilman, A.G., Rail, T.W., Nies, A.S., and Taylor, P., eds., McGraw-Hill, Inc., New York, 1992, pp. 764-783.
16. B orchard, U. Calcium antagonist in comparison: view of the pharmacologist. J. Cardiovasc. /V/an.,24(2):S85-S91,1994.
17. Stagni, G. and Gillespie, W. Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography. J. Chromatogr., 667:349-354,1995.
18. Ettl, A., Daxer, A., and Hofmann, U. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol., 116 [letter]:778-780, 1993.
19. Erickson, K., Schroeder, A., and Netland, P. Verapamil increases outflow facility in the human eye. Exp. Eye Res., 61:565-567,1995.
20. Godfraind, T. and Govoni, S. Increasing complexity revealed in regulation of Ca2+ antagonist receptor. Trends Pharmacol., 10:297-301,1989.
21. Wangemann, P., Shiga, N., Welch, C., and Marcus, D.C. Evidence for the involvement of a K channel in isosmotic cell shrinking in vestibular dark cells. Am. J. Physiol., 263:C616-C622,1992.
22. Burstein, N.L. and Anderson, J.A. Review: corneal penetration and ocular bioavailability of drugs. J. Ocular Pharmacol., 1:309-326, 1985.
23. Shell, J. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol., 26:207-218, 1982.
24. Mishima, S. Clinical pharmacokinetics of the eye. Proctor lecture. Invest. Ophthalmol. Vis. Sei., 21:504-541,1981.
25. Anderson,!. Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch. Ophthalmol., 98:350-353,1980.
26. Lee, V. and Robinson, J. Disposition of pilocarpine in the pigmented rabbit eye. Int. J. Pharmacol., 11:155-165,1982.
27. Rabiah, P., Fiscella, R., and Tessler, H. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest. Ophthalmol. Vis. Sei., 31:613-618,1996.
28. Hayreh, S.S. Fluids in the anterior part of the optic nerve in health and disease. Surv. Ophthalmol., 23:1-25, 1978.
29. Cochereau-Massin, L, Bauchet, J., Marrakchi-Benjaafar, M., Saleh-Mghir, A., Faurisson, F., Vallois, J.M., Vallée, E., and Pocidalo, JJ. Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob. Agents Chemother., 37:633-636,1993.
30. Acheampong, A.A., Breau, A., Shackleton, M., Luo, W., Lam, S., and Tang-Liu, D. Comparison of concentration-time profiles of levovunolol and timolol in anterior and posterior ocular tissues of albino rabbits. J. Ocular Pharmacol. Therap., 11:489-502, 1995.
31. Fantes, F.E., Heuer, O.K., Parrish, R.K., Sossi, N., and Gressel, M.G. Topical fluorouracil. Pharmacokinetics in normal rabbit eyes. Arch. Ophthalmol., 103:953-955,1985.
32. Ahmed, I. and Patton, T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sei., 26:584-587,1985.
33. Shichi, H. and Nebert, D.W. Drug metabolism in ocular tissues. In Extrahepatic metabolism of
34. drugs and other foreign compounds, Gram, T.E., ed., S.P. Medical and Scientific, New York, 1980, pp. 333-363.
35. Reddy, V.N. and Unakar, N.J. Localization of gamma-glutamyl transpeptidase in rabbit lens, ciliary process and cornea. Exp. Eye Res., 17:405-408,1973.
36. Das, N.D. and Shichi, H. Enzymes of mercapturate synthesis and other drug-metabolizing reactions- specific localization in the eye. Exp. Eye Res., 33:525-533, 1981.
37. Schwartzman, M.L., Masferrer, J., Dunn, M.W., McGiff, J.C., and Abraham, N.G. Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues. Ciirr. Eye Res., 6:623-630,1987.
38. Lee, V.H. Esterase activities in adult rabbit eyes. J. Pharm. Sei., 72:239-244, 1983.
39. Nakamura, M., Shirasawa, E., and Hikida, M. Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride. Ophthalmic Res., 25:46-51,1993.